Literature DB >> 30099108

AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review.

Jean-Frederic Colombel1, Andrea Shin2, Peter R Gibson3.   

Abstract

DESCRIPTION: The purpose of this clinical practice update review is to describe key principles in the diagnosis and management of functional gastrointestinal (GI) symptoms in patients with inflammatory bowel disease (IBD).
METHODS: The evidence and best practices summarized in this manuscript are based on relevant scientific publications, systematic reviews, and expert opinion where applicable. Best practice advice 1: A stepwise approach to rule-out ongoing inflammatory activity should be followed in IBD patients with persistent GI symptoms (measurement of fecal calprotectin, endoscopy with biopsy, cross-sectional imaging). Best practice advice 2: In those patients with indeterminate fecal calprotectin levels and mild symptoms, clinicians may consider serial calprotectin monitoring to facilitate anticipatory management. Best practice advice 3: Anatomic abnormalities or structural complications should be considered in patients with obstructive symptoms including abdominal distention, pain, nausea and vomiting, obstipation or constipation. Best practice advice 4: Alternative pathophysiologic mechanisms should be considered and evaluated (small intestinal bacterial overgrowth, bile acid diarrhea, carbohydrate intolerance, chronic pancreatitis) based on predominant symptom patterns. Best practice advice 5: A low FODMAP diet may be offered for management of functional GI symptoms in IBD with careful attention to nutritional adequacy. Best practice advice 6: Psychological therapies (cognitive behavioural therapy, hypnotherapy, mindfulness therapy) should be considered in IBD patients with functional symptoms. Best practice advice 7: Osmotic and stimulant laxative should be offered to IBD patients with chronic constipation. Best practice advice 8: Hypomotility agents or bile-acid sequestrants may be used for chronic diarrhea in quiescent IBD. Best practice advice 9: Antispasmodics, neuropathic-directed agents, and anti-depressants should be used for functional pain in IBD while use of opiates should be avoided. Best practice advice 10: Probiotics may be considered for treatment of functional symptoms in IBD. Best practice advice 11: Pelvic floor therapy should be offered to IBD patients with evidence of an underlying defecatory disorder. Best practice advice 12: Until further evidence is available, fecal microbiota transplant should not be offered for treatment of functional GI symptoms in IBD. Best practice advice 13: Physical exercise should be encourage in IBD patients with functional GI symptoms. Best practice advice 14: Until further evidence is available, complementary and alternative therapies should not be routinely offered for functional symptoms in IBD. This Clinical Practice Update was produced by the AGA Institute.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30099108      PMCID: PMC6581193          DOI: 10.1016/j.cgh.2018.08.001

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  75 in total

1.  How to avoid treating irritable bowel syndrome with biologic therapy for inflammatory bowel disease.

Authors:  William J Sandborn
Journal:  Dig Dis       Date:  2010-03-04       Impact factor: 2.404

2.  Is rifaximin effective in maintaining remission in Crohn's disease?

Authors:  Anca Olivia Jigaranu; Otilia Nedelciuc; Andreea Blaj; Mircea Badea; Catalina Mihai; Mircea Diculescu; Cristina Cijevschi-Prelipcean
Journal:  Dig Dis       Date:  2014-06-23       Impact factor: 2.404

3.  Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis.

Authors:  Anish Patel; Hinaben Panchal; Marla C Dubinsky
Journal:  Inflamm Bowel Dis       Date:  2017-09       Impact factor: 5.325

4.  Symptoms in patients with ulcerative colitis in remission are associated with visceral hypersensitivity and mast cell activity.

Authors:  Eduard A van Hoboken; Annemieke Y Thijssen; Rob Verhaaren; Patrick P J van der Veek; Frans A Prins; Hein W Verspaget; Ad A M Masclee
Journal:  Scand J Gastroenterol       Date:  2011-05-30       Impact factor: 2.423

5.  Gastrointestinal and psychological mediators of health-related quality of life in IBS and IBD: a structural equation modeling analysis.

Authors:  Bruce D Naliboff; Sharon E Kim; Roger Bolus; Charles N Bernstein; Emeran A Mayer; Lin Chang
Journal:  Am J Gastroenterol       Date:  2011-11-15       Impact factor: 10.864

6.  Benefit of computed tomography enterography in Crohn's disease: effects on patient management and physician level of confidence.

Authors:  David H Bruining; Hassan A Siddiki; Joel G Fletcher; William J Sandborn; Jeff L Fidler; James E Huprich; Jayawant N Mandrekar; William S Harmsen; Paul E Evans; William A Faubion; Karen A Hanson; Steven B Ingle; Darrell S Pardi; Kenneth W Schroeder; William J Tremaine; Edward V Loftus
Journal:  Inflamm Bowel Dis       Date:  2011-02-17       Impact factor: 5.325

7.  Prevalence of proximal faecal stasis in active ulcerative colitis.

Authors:  M C Allison; R Vallance
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

8.  Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.

Authors:  Laurent Peyrin-Biroulet; Walter Reinisch; Jean-Frederic Colombel; Gerassimos J Mantzaris; Asher Kornbluth; Robert Diamond; Paul Rutgeerts; Linda K Tang; Freddy J Cornillie; William J Sandborn
Journal:  Gut       Date:  2013-08-23       Impact factor: 23.059

9.  Fermentable Carbohydrates [FODMAPs] Exacerbate Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: A Randomised, Double-blind, Placebo-controlled, Cross-over, Re-challenge Trial.

Authors:  Selina R Cox; Alexis C Prince; Clio E Myers; Peter M Irving; James O Lindsay; Miranda C Lomer; Kevin Whelan
Journal:  J Crohns Colitis       Date:  2017-12-04       Impact factor: 9.071

10.  Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis.

Authors:  B Jharap; W J Sandborn; W Reinisch; G D'Haens; A M Robinson; W Wang; B Huang; A Lazar; R B Thakkar; J-F Colombel
Journal:  Aliment Pharmacol Ther       Date:  2015-09-03       Impact factor: 8.171

View more
  33 in total

1.  Adherence to Mediterranean diet in Crohn's disease.

Authors:  Efstathia Papada; Charalampia Amerikanou; Alastair Forbes; Andriana C Kaliora
Journal:  Eur J Nutr       Date:  2019-04-20       Impact factor: 5.614

2.  High-Fat Diet and Antibiotics Cooperatively Impair Mitochondrial Bioenergetics to Trigger Dysbiosis that Exacerbates Pre-inflammatory Bowel Disease.

Authors:  Jee-Yon Lee; Stephanie A Cevallos; Mariana X Byndloss; Connor R Tiffany; Erin E Olsan; Brian P Butler; Briana M Young; Andrew W L Rogers; Henry Nguyen; Kyongchol Kim; Sang-Woon Choi; Eunsoo Bae; Je Hee Lee; Ui-Gi Min; Duk-Chul Lee; Andreas J Bäumler
Journal:  Cell Host Microbe       Date:  2020-07-14       Impact factor: 21.023

Review 3.  Popular Diet Trends for Inflammatory Bowel Diseases: Claims and Evidence.

Authors:  Andrew T Weber; Neha D Shah; Jenny Sauk; Berkeley N Limketkai
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12

Review 4.  Nutraceuticals as modulators of gut microbiota: Role in therapy.

Authors:  Eamonn M M Quigley
Journal:  Br J Pharmacol       Date:  2020-01-03       Impact factor: 8.739

5.  Symptoms among emerging adults with inflammatory bowel disease: a descriptive study.

Authors:  Kendra Kamp; Sharon Dudley-Brown; Margaret Heitkemper; Gwen Wyatt; Barbara Given
Journal:  Res Nurs Health       Date:  2019-10-10       Impact factor: 2.228

6.  [Clinical guidelines for the diagnosis and treatment of neonatal necrotizing enterocolitis (2020)].

Authors: 
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2021-01

Review 7.  Brain-Gut Therapies for Pediatric Functional Gastrointestinal Disorders and Inflammatory Bowel Disease.

Authors:  Hannibal Person; Laurie Keefer
Journal:  Curr Gastroenterol Rep       Date:  2019-03-12

Review 8.  Abnormal gut motility in inflammatory bowel disease: an update.

Authors:  G Bassotti; E Antonelli; V Villanacci; R Nascimbeni; M P Dore; G M Pes; G Maconi
Journal:  Tech Coloproctol       Date:  2020-02-15       Impact factor: 3.781

Review 9.  Managing Pain and Psychosocial Care in IBD: a Primer for the Practicing Gastroenterologist.

Authors:  Emily Weaver; Eva Szigethy
Journal:  Curr Gastroenterol Rep       Date:  2020-03-17

Review 10.  Gastrointestinal pain.

Authors:  Asbjørn M Drewes; Anne E Olesen; Adam D Farmer; Eva Szigethy; Vinciane Rebours; Søren S Olesen
Journal:  Nat Rev Dis Primers       Date:  2020-01-06       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.